09
2021-04
Kintor Announces Presentation of Preclinical Data at AACR 2021
Suzhou, Apr.9, 2021--真人直营投注网站 , a clinical-stage biotechnology company developing small molecule and biological therapeutics, today announced two poster presentations of preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021, including proxalutamide(GT0918) to treat COVID-19 and a c-Myc inhibitor to treat blood cancer.
26
2021-03
Kintor Announces 2020 Business Progress and Annual Results
Suzhou, Mar.26, 2021--真人直营投注网站 (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial results for the year ended December 31, 2020.
11
2021-03
SUZHOU, China, Mar 11, 2021--真人直营投注网站 (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale. In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline of 5.663 to 1.653 in the Proxalutamide arm versus a reduction of 0.25 from a baseline of 5.618 to 5.368 in the control arm with a p value <0.0001. Proxalutamide also demonstrated a reduction in mortality risk by 92% (3.7% vs 47.6%) and shortened median hospital length stayby 9 days (median hospital stay of 5 days vs 14 days).
05
2021-03
Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA
Suzhou, Mar.5, 2021--真人直营投注网站 is pleased to announce that the Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide’s treatment of male COVID-19 outpatients has been approved by the United States Food and Drug Administration (FDA).
22
2021-02
Completion of Patients’Recruitment for Proxalutamide’s COVID-19 Hospitalised Study
Suzhou, Feb.22, 2021--真人直营投注网站 is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients in Brazil completed the recruitment of 588 patients. The data of the clinical trial is expected to be available in March 2021.
18
2021-02
Suzhou, Feb.18, 2021--真人直营投注网站 (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT90001 for a multi-regional phase II clinical trial for combination treatment of GT90001 and Nivolumab (Opdivo®) for the second-line treatment of advanced hepatocellular carcinoma (“HCC”) was approved by the Food and Drug Administration (the "US FDA") on February 11, 2021.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn